News | July 02, 2022
Lonza to invest 500 mn in commercial drug product fill & finish facility
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
The investment will enable the company to provide customers with a complete and integrated end-to-end solution
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
States have an important role in ensuring food safety and healthy food practices.
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Each member of Fitelo's team of experts gives highly personalized attention and recommendations to their clients ensuring they reach their fitness goals holis
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
Subscribe To Our Newsletter & Stay Updated
